NCT02033148

Icotinib Hydrochloride in Treating Patients With Advanced Cancers

Name: Clinical Trial NCT02033148
Creator: Roswell Park Cancer Institute
Keywords: Unspecified Adult Solid Tumor, Protocol Specific, icotinib hydrochloride, Phase 1, drug, clinical trial

A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of Icotinib in Patients With Advanced Cancers

Roswell Park Cancer Institute·Phase 1·ClinicalTrials.gov·drugWithdrawn

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention: icotinib hydrochloride
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Roswell Park Cancer Institute

Timeline & enrollment

Phase: Phase 1
Start date: Aug 01, 2014
End date: N/A
Enrollment: 0 participants

Primary outcome

MTD of icotinib hydrochloride, defined as the highest dose level at which = 1 of 6 evaluable patients experiences a dose-limiting toxicity, as graded using NCI CTCAE version 4.0,PK parameters of icotinib hydrochloride

Summary

This phase I trial studies the side effects and best dose of icotinib hydrochloride in treating patients with advanced cancers. Icotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

ICD-10 classifications

Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT02033148
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT02033148 through Pure Global AI's free database. This Phase 1 trial is sponsored by Roswell Park Cancer Institute and is currently Withdrawn. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 0 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.